ANGLE plc (GB:AGL) has released an update.
ANGLE plc, a leading liquid biopsy company, has announced the European Patent Office’s grant of a patent for its CellKeep™ slide, which promises over 70% reduction in circulating tumour cell (CTC) loss during analysis, a common issue with standard microscopy techniques. The technology, which is also expected to receive a US patent, significantly improves CTC capture and analysis, potentially advancing cancer diagnostics and precision medicine. The CellKeep slide is a key component of ANGLE’s Portrait®+ CTC staining kit, used with their Parsortix system for efficient CTC harvesting from blood samples.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
